CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (436,367)	$ (248,705)	$ (187,091)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of fixed assets	52	19	119
Amortization of intangible assets	1,068	1,069	1,069
Stock-based compensation expense	61,772	31,196	20,724
Depreciation	5,042	3,972	3,083
Change in fair value of warrant liability and contingent earn-out shares	115	0	0
Net amortization of premium or discount on marketable securities	(22,205)	(3,078)	3,012
Amortization of operating lease right-of-use asset	3,199	4,615	3,180
Changes in operating assets and liabilities:
Accounts receivable	3,419	1,256	464
Prepaid expenses and other current assets	(2,646)	(3,779)	198
Accounts payable	32,469	7,288	2,239
Accrued expenses and other current liabilities	14,668	1,502	8,720
Deferred revenue	(4,459)	(14,472)	(1,661)
Operating lease liability	(1,532)	(2,428)	(1,468)
Deferred tax liability	(3,910)	(419)	0
Other noncurrent assets	(1,414)	(2,247)	81
Other noncurrent liabilities	157	(190)	151
Net cash used in operating activities	(350,572)	(224,401)	(147,180)
Cash flows from investing activities
Purchases of marketable securities	(1,058,916)	(612,769)	(671,335)
Maturities of marketable securities	724,047	599,469	526,754
Sales of marketable securities	0	0	8,992
Purchases of property and equipment	(7,729)	(10,816)	(6,528)
Net cash used in investing activities	(342,598)	(24,116)	(142,117)
Cash flows from financing activities
Cash, cash equivalents and restricted cash acquired in connection with EQRx Acquisition, net of transaction costs	840,834	0	0
Proceeds from issuance of common stock, net of issuance costs	323,706	248,126	281,145
Proceeds from issuance of common stock from at-the-market offering, net of transaction costs	62,053	49,919	10,096
Proceeds from issuance of common stock under equity incentive plans	3,316	1,481	1,487
Proceeds from issuance of common stock under employee stock purchase plan	3,317	1,864	1,875
Tax payment for common stock withheld in satisfaction of withholding tax requirements	(4,026)	0	0
Payments of deferred offering costs	0	42	(424)
Net cash provided by financing activities	1,229,200	301,432	294,179
Net increase in cash, cash equivalents and restricted cash	536,030	52,915	4,882
Cash, cash equivalents and restricted cash - beginning of year	163,149	110,234	105,352
Cash, cash equivalents and restricted cash - end of year	699,179	163,149	110,234
Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets
Cash and cash equivalents	696,148	161,412	108,497
Restricted cash	3,031	1,737	1,737
Cash, cash equivalents and restricted cash - end of period	699,179	163,149	110,234
Supplemental disclosure of non-cash investing and financing activities
Issuance of common stock for EQRx acquisition	1,085,676	0	0
Fair value of net assets acquired in connection with EQRx Acquisition	291,475	0	0
EQRx acquisition transaction costs incurred but not paid	100	0	0
Vesting of early exercised options and restricted stock	0	143	149
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	2,611	1,419	1,129
Advance payments for property and equipment	180	82	0
Right-of-use assets obtained in exchange for operating lease liabilities	25,271	0	35,437
Unpaid/deferred offering costs	$ 2	$ 2	$ 110